Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by King Faisal Specialist Hospital & Research Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT01310972
First received: March 6, 2011
Last updated: December 11, 2011
Last verified: December 2011
  Purpose

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX


Condition Intervention
Colon Cancer
Other: Registry

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Resource links provided by NLM:


Further study details as provided by King Faisal Specialist Hospital & Research Center:

Estimated Enrollment: 6
Study Start Date: September 2007
Intervention Details:
    Other: Registry
    Registry
    Other Name: Registry
Detailed Description:

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

  Eligibility

Ages Eligible for Study:   14 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Colon Cancer Registry

Criteria

Inclusion Criteria:

  • Patients with Adjuvant Colon Cancer

Exclusion Criteria:

  • Patients with diagnosis other than Colon Cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01310972

Contacts
Contact: Al Jubran, M.D. +966-1-4423949

Locations
Saudi Arabia
Kfsh & Rc Recruiting
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Al Jubran, M.D. KFSH & RC
  More Information

No publications provided

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT01310972     History of Changes
Other Study ID Numbers: RAC# 2071-027, RAC# 2071-027
Study First Received: March 6, 2011
Last Updated: December 11, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by King Faisal Specialist Hospital & Research Center:
Adjuvant Colon Cancer

Additional relevant MeSH terms:
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Oxaliplatin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014